Thera-SAbDab

LULIZUMAB

>   Structural Summary
TherapeuticLulizumab
TargetCD28
Heavy Chainna
Light ChainDIQMTQSPSSLSASVGDRVTITCRASRPIWPFLEWYQQKPGKAPKLLIYFTSRLRHGVPSRFSGSGSGTCFTLTISSLQPEDFATYYCLQNVANPATFSQGTKVEIK
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatSingle Domain Variable Fragment;L
Isotypena
Highest Clinical Trial (October '21)Phase-II
Estimated Status (October '21)Active
Recorded Developmental Technologyna
INN Year Proposed2014
INN Year Recommended2015
Companies InvolvedBristol-Myers Squibb
Conditions Approvedna
Conditions ActiveSjogren's syndrome, Systemic lupus erythematosus, Renal transplant rejection
Conditions Discontinuedna
Notes

SAbDab papers

Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]

Dunbar, J., Krawczyk, K. et al. (2014) SAbDab: the Structural Antibody Database. Nucleic Acids Res. 42(D1):D1140-D1146 [link]

Thera-SAbDab paper

Raybould, M.I.J., Marks, C. et al (2020) Thera-SAbDab: the Therapeutic Structural Antibody Database. Nucleic Acids Res. 48(D1):D383-D388. [link]

Our privacy policy